<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070083</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000329985</org_study_id>
    <secondary_id>BCCA-NCI-5818</secondary_id>
    <secondary_id>NCI-5818</secondary_id>
    <nct_id>NCT00070083</nct_id>
  </id_info>
  <brief_title>Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase I Study Of G3139 Antisense Oligonucleotide (Oblimersen) In Combination With CHOP And Rituximab In Untreated Advanced Stage Diffuse Large B Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>British Columbia Cancer Agency</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill&#xD;
      them or deliver cancer-killing substances to them without harming normal cells. Drugs used in&#xD;
      chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use&#xD;
      different ways to stop cancer cells from dividing so they stop growing or die. Oblimersen may&#xD;
      increase the effectiveness of a chemotherapy drug by making cancer cells more sensitive to&#xD;
      the drug. Combining oblimersen with rituximab and combination chemotherapy may kill more&#xD;
      cancer cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of oblimersen when&#xD;
      given together with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in&#xD;
      treating patients with stage II, stage III, or stage IV large B-cell lymphoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the feasibility and safety of oblimersen administered in combination with&#xD;
           rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, in terms of&#xD;
           short-term and long-term toxicity, in patients with previously untreated stage III or IV&#xD;
           or extensive or bulky stage II diffuse large B-cell lymphoma.&#xD;
&#xD;
        -  Determine the maximum tolerated dose of oblimersen administered with this regimen in&#xD;
           these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the remission rate and failure-free, progression-free, and overall survival of&#xD;
           patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, non-blinded, multicenter, dose-escalation study of&#xD;
      oblimersen.&#xD;
&#xD;
      Patients receive CHOP-R* therapy comprising cyclophosphamide IV over 15-45 minutes,&#xD;
      doxorubicin IV over 5-10 minutes, vincristine IV, and rituximab IV over 30-90 minutes on day&#xD;
      1 and oral prednisone on days 1-5. Patients also receive oblimersen IV continuously on days&#xD;
      -4 to 3. Treatment repeats every 21 days for 6-8 courses in the absence of disease&#xD;
      progression or unacceptable toxicity. Patients who discontinue treatment due to unacceptable&#xD;
      toxicity to oblimersen may continue to receive standard therapy comprising CHOP-R.&#xD;
&#xD;
      NOTE: *Patients treated at the British Columbia Cancer Agency receive cyclophosphamide,&#xD;
      doxorubicin, vincristine, and rituximab on days 1 and 2 and prednisone as above.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of oblimersen until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 10&#xD;
      patients are treated at that dose level.&#xD;
&#xD;
      Patients are followed every 3 months for 2 years, every 4 months for 1 year, every 6 months&#xD;
      for 2 years, and then annually thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 19-28 patients will be accrued for this study within 5-10&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>oblimersen sodium</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rituximab</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vincristine sulfate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed* CD20+ diffuse large B-cell lymphoma, including any of the&#xD;
             following stages:&#xD;
&#xD;
               -  Extensive stage II (not radio-encompassable within a single involved field or not&#xD;
                  a candidate for brief chemotherapy and radiotherapy)&#xD;
&#xD;
               -  Bulky stage II (any single mass greater than 10 cm)&#xD;
&#xD;
               -  Stage III&#xD;
&#xD;
               -  Stage IV NOTE: *Confirmed by tissue biopsy&#xD;
&#xD;
          -  Previously untreated disease&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least 2 cm by imaging studies&#xD;
&#xD;
          -  Circulating lymphoma cells no greater than 5,000/mm^3&#xD;
&#xD;
          -  No history of other lymphoproliferative disorder&#xD;
&#xD;
          -  No history of indolent lymphoma&#xD;
&#xD;
          -  No T-cell lymphoma&#xD;
&#xD;
          -  No CNS involvement&#xD;
&#xD;
          -  No post-transplantation lymphoproliferative disorder&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  19 and over&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3 (unless due to bone marrow involvement&#xD;
             with lymphoma)&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (unless due to splenomegaly or bone marrow&#xD;
             involvement with lymphoma)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 3 mg/dL (unless due to lymphoma)&#xD;
&#xD;
          -  No known hepatitis B virus&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL (unless due to lymphoma)&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No cardiac contraindication to doxorubicin therapy (e.g., abnormal contractility on&#xD;
             echocardiography)&#xD;
&#xD;
          -  History of cardiac disease allowed provided ejection fraction is normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Adequate venous access&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer, localized basal cell or squamous cell skin cancer, or curatively treated&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  No neurological contraindication to vincristine (e.g., peripheral neuropathy)&#xD;
&#xD;
          -  No active systemic infection&#xD;
&#xD;
          -  No medical condition that would compromise study treatment, add toxicity, or impair&#xD;
             assessment&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  No prior systemic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy&#xD;
&#xD;
               -  Prior radiotherapy for localized basal cell or squamous cell skin cancer used&#xD;
                  with curative intent allowed&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard J. Klasa, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford Cancer Center at Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fraser Valley Cancer Centre at British Columbia Cancer Agency</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2005</verification_date>
  <study_first_submitted>October 3, 2003</study_first_submitted>
  <study_first_submitted_qc>October 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2003</study_first_posted>
  <last_update_submitted>April 4, 2009</last_update_submitted>
  <last_update_submitted_qc>April 4, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2009</last_update_posted>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

